TOP2A gene copy number change in breast cancer
Authors:
Open Access
- 8 January 2014
- journal article
- research article
- Published by BMJ in Journal of Clinical Pathology
- Vol. 67 (5) , 420-425
Abstract
Aims: The clinical significance of TOP2A as a prognostic marker has not been clarified. The aims of this study were to investigate the frequency of TOP2A copy number change; to correlate TOP2A with HER2 status, hormone receptor (HR) status and molecular subtype, and further to explore differences in breast cancer-specific survival according to TOP2A and HER2. Methods: In this study, TOP2A, HER2 and chromosome 17 copy number were assessed in 670 cases of breast cancer using in situ hybridisation techniques. Gene to chromosome ratios ≥2 were classified as amplification. TOP2A deletion (gene to chromosome ratio ≤0.8) or monosomy (only one signal for both gene and chromosome in more than 75% of nuclei) were classified as gene loss. Results: A strong association between TOP2A change and HR and HER2 status was found. During the first 5 years after diagnosis, the risk of death from breast cancer was significantly higher for cases with HER2 amplification irrespective of TOP2A status. Conclusions: TOP2A copy number change was strongly associated with HR and HER2 status and as a prognostic marker TOP2A is probably of limited value.Keywords
This publication has 21 references indexed in Scilit:
- Molecular subtypes, histopathological grade and survival in a historic cohort of breast cancer patientsBreast Cancer Research and Treatment, 2013
- Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trialsBMC Cancer, 2013
- TOP2A RNA expression and recurrence in estrogen receptor-positive breast cancerBreast Cancer Research and Treatment, 2012
- HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient dataThe Lancet Oncology, 2011
- Joint effects of nulliparity and other breast cancer risk factorsBritish Journal of Cancer, 2011
- HER2 testing in the UK: recommendations for breast and gastric in-situ hybridisation methodsJournal of Clinical Pathology, 2011
- Assessment of Topoisomerase II α Status in Breast Cancer by Quantitative PCR, Gene Expression Microarrays, Immunohistochemistry, and Fluorescence in Situ HybridizationThe American Journal of Pathology, 2011
- Guidelines for Human Epidermal Growth Factor Receptor 2 Testing: Biologic and Methodologic ConsiderationsJournal of Clinical Oncology, 2009
- Gene expression of topoisomerase II alpha (TOP2A) by microarray analysis is highly prognostic in estrogen receptor (ER) positive breast cancerBreast Cancer Research and Treatment, 2008
- Topoisomerase II-α (topoII) and HER2 amplification in breast cancers and response to preoperative doxorubicin chemotherapyEuropean Journal of Cancer, 2003